DOP2001000164A - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
DOP2001000164A
DOP2001000164A DO2001000164A DO2001000164A DOP2001000164A DO P2001000164 A DOP2001000164 A DO P2001000164A DO 2001000164 A DO2001000164 A DO 2001000164A DO 2001000164 A DO2001000164 A DO 2001000164A DO P2001000164 A DOP2001000164 A DO P2001000164A
Authority
DO
Dominican Republic
Prior art keywords
ryk
diseases
angiogenesis
ryk protein
protein
Prior art date
Application number
DO2001000164A
Other languages
English (en)
Inventor
Alya Zolotorev
Steve Roczniak
Nathalie A Dubois-Stringfellow
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DOP2001000164A publication Critical patent/DOP2001000164A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se encontró que La proteína Ryk tenía una novedosa actividad en la regulación de la angiogénesis. Se construyeron nuevas proteínas Ryk variantes Que son ventajosas para modular la actividad formadora de capilares de las células endoteliales. Las proteínas Ryk variantes pueden ser utilizadas como agentes terapéuticos en enfermedades tales como el cáncer, la cicatrización de heridas, las retinopatías diabéticas, la degeneración macular y las enfermedades cardiovasculares, así como otras enfermedades o trastornos clínicos en la que la Angiogénesis está involucrada en la causa o el tratamiento de la enfermedad.
DO2001000164A 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk DOP2001000164A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
DOP2001000164A true DOP2001000164A (es) 2002-05-15

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2001000164A DOP2001000164A (es) 2000-05-10 2001-05-10 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (es)
JP (1) JP2004527206A (es)
AR (1) AR028424A1 (es)
AU (1) AU2001261343A1 (es)
CA (1) CA2408349A1 (es)
CO (1) CO5300464A1 (es)
DO (1) DOP2001000164A (es)
EC (1) ECSP014068A (es)
GT (1) GT200100079A (es)
PE (1) PE20011218A1 (es)
SV (1) SV2002000442A (es)
UY (1) UY26696A1 (es)
WO (1) WO2001085789A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003066087A2 (en) * 2002-02-06 2003-08-14 Developgen Aktiengesellschaft Für Entwicklungsbiologische Forschung Kinases involved in the regulation of energy homeostasis
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
DK3170005T3 (da) 2014-07-18 2019-07-08 Sanofi Sa Fremgangsmåde til forudsigelse af resultatet af en behandling med aflibercept hos en patient, der mistænkes for at lide af cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07506969A (ja) * 1992-05-11 1995-08-03 ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ レセプタ型チロシンキナーゼ類似の分子
KR19980701950A (ko) * 1994-12-23 1998-06-25 에드워드 에이. 맥더모 2세, 로이드 제이. 오울드 분석, 리셉터 단백질 및 리간드
DE69930662T2 (de) * 1998-06-11 2006-12-28 Astrazeneca Ab Humane rezeptortyrosinkinase
ATE406907T1 (de) * 1998-10-28 2008-09-15 Cornell Res Foundation Inc Methoden zur regulierung der angiogenese und vaskuläre integrität mittels trk rezeptor liganden bdnf, nt-3 und nt-4

Also Published As

Publication number Publication date
JP2004527206A (ja) 2004-09-09
AU2001261343A1 (en) 2001-11-20
GT200100079A (es) 2001-12-31
CO5300464A1 (es) 2003-07-31
SV2002000442A (es) 2002-07-03
ECSP014068A (es) 2002-02-25
AR028424A1 (es) 2003-05-07
WO2001085789A2 (en) 2001-11-15
WO2001085789A3 (en) 2002-05-16
PE20011218A1 (es) 2002-02-01
CA2408349A1 (en) 2001-11-15
EP1287121A2 (en) 2003-03-05
UY26696A1 (es) 2001-12-28

Similar Documents

Publication Publication Date Title
UY28396A1 (es) Trompas de vegf y usos terapéuticos de las mismas
ATE290401T1 (de) Topisch anwendbare mittel gegen nagelpilzerkrankungen
DK1641483T3 (da) Fusionsproteiner
IL117645A (en) Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
TR200101307T2 (tr) Antranilik asit amidler ve ilaç olarak kullanılmaları.
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ES2157422T3 (es) Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
DE602005020178D1 (de) 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten
PT1343472E (pt) Pulverizacao nasal tixotropica
DOP2001000164A (es) Metodo para regular la angiogenesis utilizando proteina ryk
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
DE60107444D1 (de) Verwendung einer pollenextrakt-enthaltenden verbindung zur behandlung von ödemen
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ATE555787T1 (de) Behandlungseffekte von überschüssigen reaktiven sauerstoffspezies
AR027764A1 (es) Proteinas que tienen actividad como modulador de angiogenesis
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
SV2002000362A (es) Proteinas que tienen una actividad moduladora de angiogenesis ref.msb-7265-sv
ATE374048T1 (de) Verwendung von matrixprotein für gesteuerte geweberegenerationen
TR199901385T2 (xx) Piperidin t�revleri.
AR011907A1 (es) UTILIZACIoN DEL ACIDO 4-(2,2-DIMETILPROPANOL)BUTANOICO (PIVAGABIN)PARA PREPARAR UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE FORMAS DE ANSIEDADDEPRESIVA.
WO2001074852A3 (en) Protein having activity as an angiogenesis modulator
DE60122764D1 (de) Verwendung von cortisol-sequestriermitteln zur behandlung von hypercortisolaemie-verwandten erkrankungen
SV1994000023A (es) Pirroles sustituidos ref. ran 4070/90
DE60234786D1 (de) Peptid-köder zur herstellung von medikamenten, die für die prävention oder behandlung von autoimmunerkrankungen bzw. problemen, die mit dem auftreten von gegen exogene proteine gerichteten antikörpern in zusammenhang stehen, bestimmt sind
PE122099A1 (es) Budesonida sola o en combinacion con acido ursodesoxicolico en la terapia de enfermedades colestasicas del higado